Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24153475 | 0.91 | KMT2A (0.38) | MAPTNPY1RHTR1ATHRBLMNA | |
| SCHEMBL24938892 | 0.90 | NPY1R (0.41) | NPY1RHTR1ATHRBLMNA | |
| SCHEMBL24939891 | 0.90 | LMNA (0.42) | MAPTNPY1RHTR1ATHRBLMNA | |
| SCHEMBL24939892 | 0.89 | LMNA (0.38) | MAPTNPY1RHTR1ATHRBLMNA | |
| SCHEMBL24153613 | 0.89 | NPY1R (0.36) | MAPTNPY1RHTR1ATHRBLMNA | |
| SCHEMBL24939973 | 0.89 | NPY1R (0.36) | MAPTNPY1RHTR1ATHRBLMNA | |
| SCHEMBL24153499 | 0.89 | HTR1A (0.39) | NPY1RHTR1A | |
| SCHEMBL24153472 | 0.88 | HTR1A (0.39) | NPY1RHTR1A | |
| SCHEMBL24939924 | 0.88 | L3MBTL1 (0.41) | MAPTNPY1R | |
| SCHEMBL24938971 | 0.87 | NPY1R (0.39) | NPY1RHTR1ATHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | HOLOSMEDIC (KR) | 2023-01-19 | — | — | US | disclosed |
| WO-2021086038-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | 홀로스메딕 주식회사 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | MAPT 4096/4885NPY1R 4531/4885HTR1A 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.